Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019

S M Qasim Hussaini; Arjun Gupta; Kelly E Anderson; Jeromie M Ballreich; Lauren Hersch Nicholas; G Caleb Alexander

doi:10.1001/jamanetworkopen.2022.1117

Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019

JAMA Netw Open. 2022 Mar 1;5(3):e221117. doi: 10.1001/jamanetworkopen.2022.1117.

Authors

S M Qasim Hussaini¹, Arjun Gupta², Kelly E Anderson³, Jeromie M Ballreich^{4

5}, Lauren Hersch Nicholas⁶, G Caleb Alexander^{4

5

7

8}

Affiliations

¹ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland.
² Masonic Cancer Center, University of Minnesota, Minneapolis.
³ Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora.
⁴ Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
⁵ Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
⁶ Department of Health Systems, Management & Policy, University of Colorado Anschutz Medical Campus, Aurora.
⁷ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
⁸ Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland.

Abstract

This cross-sectional study examines utilization trends for filgrastim and infliximab products and their biosimilars to understand whether biosimilars are associated with reduced spending in Medicare Part D.

Publication types

Letter
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Aged
Biosimilar Pharmaceuticals* / therapeutic use
Filgrastim / therapeutic use
Humans
Infliximab / therapeutic use
Medicare Part D*
United States

Substances

Biosimilar Pharmaceuticals
Infliximab
Filgrastim

Grants and funding

T32 HS000029/HS/AHRQ HHS/United States